Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Roblin

Showing results (121-130 of 252) with videos related to

Pageof 26
Sort By:
Endoscopy|April 27, 2018
Effect of Endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trialsNicolas Williet, Quentin Tournier, Chloé Vernet, et al.
Digestive Diseases (Basel, Switzerland)|August 22, 2018
Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion ReactionsIsabelle Pauchard, Stéphane Nancey, Florence Hacard, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2014
Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatmentGilles Boschetti, Stéphane Nancey, Driffa Moussata, et al.
Current Drug Targets|September 1, 2014
Pharmacokinetics in IBD: ready for prime time?Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, et al.
Therapeutic Drug Monitoring|December 2, 2024
One Concentration Does Not Fit All: It Is Time to Personalize the Therapeutic Range of Infliximab in Crohn DiseaseBénédicte Franck, Camille Tron, Marie-Clémence Verdier, et al.
Journal of Crohn'S & Colitis|January 24, 2016
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre ExperienceLaurent Peyrin-Biroulet, Julia Salleron, Jérôme Filippi, et al.
International Journal of Molecular Sciences|September 9, 2022
Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug AntibodiesAnne Emmanuelle Berger, Aude Gleizes, Louis Waeckel, et al.
Oncotarget|September 4, 2018
Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancersNicolas Williet, Thomas Di Bernardo, Chloé Vernet, et al.
Inflammatory Bowel Diseases|February 8, 2024
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional StudyLea Derbey, Anne Laure Charlois, Anthony Buisson, et al.
Inflammatory Bowel Diseases|November 6, 2021
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's DiseaseXavier Roblin, Adrian Serone, Oh Kyu Yoon, et al.
Pageof 26

Showing results (121-130 of 252) with videos related to

Sort By:
Pageof 26
Endoscopy|April 27, 2018
Effect of Endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trialsNicolas Williet, Quentin Tournier, Chloé Vernet, et al.
Digestive Diseases (Basel, Switzerland)|August 22, 2018
Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion ReactionsIsabelle Pauchard, Stéphane Nancey, Florence Hacard, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2014
Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatmentGilles Boschetti, Stéphane Nancey, Driffa Moussata, et al.
Current Drug Targets|September 1, 2014
Pharmacokinetics in IBD: ready for prime time?Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, et al.
Therapeutic Drug Monitoring|December 2, 2024
One Concentration Does Not Fit All: It Is Time to Personalize the Therapeutic Range of Infliximab in Crohn DiseaseBénédicte Franck, Camille Tron, Marie-Clémence Verdier, et al.
Journal of Crohn'S & Colitis|January 24, 2016
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre ExperienceLaurent Peyrin-Biroulet, Julia Salleron, Jérôme Filippi, et al.
International Journal of Molecular Sciences|September 9, 2022
Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10<sup>®</sup> to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug AntibodiesAnne Emmanuelle Berger, Aude Gleizes, Louis Waeckel, et al.
Oncotarget|September 4, 2018
Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancersNicolas Williet, Thomas Di Bernardo, Chloé Vernet, et al.
Inflammatory Bowel Diseases|February 8, 2024
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional StudyLea Derbey, Anne Laure Charlois, Anthony Buisson, et al.
Inflammatory Bowel Diseases|November 6, 2021
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's DiseaseXavier Roblin, Adrian Serone, Oh Kyu Yoon, et al.
Pageof 26